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Summary 
Background: The objective of this prospective study was to
evaluate whether soluble programmed cell death-
1/programmed cell death-ligand 1 (PD-1/PD-L1) and
serum amyloid A1 (SAA1) are potential diagnostic,
predictive or prognostic biomarkers in lung cancer.
Methods: Lung cancer patients (n=115) with advanced
metastatic disease, 101 with non-small cell lung cancer,
NSCLC (77 EGFR wild-type NSCLC patients on chemo -
therapy, 15 EGFR mutation positive adenocarcinoma
patients, 9 patients with mPD-L1 Expression ≥50% NSCLC
– responders to immunotherapy), and 14 patients with small
cell lung cancer (SCLC) were examined. ELISA method was
used to determine sPD-L1 and SAA1 concentrations in
patients’ plasma. 
Results: Significantly higher blood concentrations of sPD-
L1 and SAA1 were noted in lung cancer patients compared
with a healthy control group. In PD-L1+ NSCLC patients,
a significantly higher sPD-L1 level was noticed compared
Kratak sadr`aj
Uvod: Cilj ove prospektivne studije je bio da proceni da li su
solubilna forma molekula PD-1/PD-L1 (receptor za progra -
miranu }elijsku smrt-1/ligand za receptor) i serumski amiloid
A1 (SAA1) potencijalni dijagnosti~ki, prediktivni ili progno -
sti~ki biomarkeri kod karcinoma plu}a. 
Metode: Ispitivani su pacijenti sa uznapredovalim karcino -
mom plu}a (n = 115), 101 sa nesitno}elijskim karcino mom
plu}a, NSCLC (77 pacijenata sa EGFR wild type NSCLC
le~enih standardnom hemioterapijom, 15 pacije nata sa
adenokarcinomom koji ima EGFR aktivacijsku mutaciju, i 9
pacijenata sa NSCLC koji ima mPD-L1 ekspre siju ≥ 50%,
a koji su odgovorili na imunoterapiju), i 14 pacijenata sa
sitno}elijskim karcinomom plu}a (SCLC). Svim pacijentima
su odre|ene koncentracije sPD-L1 i SAA1 u plazmi ELISA
metodom. 
Rezultati: Zna~ajno vi{e koncentracije sPD-L1 i SAA1 su
uo~ene kod pacijenata sa karcinomom plu}a u pore|enju
sa kontrolnom grupom zdravih pojedinaca. Kod pacijenata
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Introduction
Immune checkpoint PD-1 plays a role in
controlling inflammatory response to injuries in
normal lung tissues and could be critical in the
pathogenesis of lung cancer. In the last decade,
immune checkpoint PD-L1 expression on cancer and
tumour-associated cells has become the target of
checkpoint inhibitor therapy that unleashes antitumor
T cells and has revolutionised cancer immunotherapy
(1–3). 
The PD-1/PD-L1 pathway molecules including
membrane-bound forms of PD-1/PD-L1 (mPD-1/
PD-L1) and recently revealed soluble forms (4, 5),
sPD-1/PD-L1, play immunosuppressive roles in
tumour-driven T-cell immune responses (4, 6). Soluble
PD-L1 could be measured in blood by immuno -
chemistry methods (4). Since chronic inflammation
was found to be associated with tumour progression,
it was assumed that many inflammatory parameters
could serve as prognostic biomarkers for some
tumours (7–9) including lung cancer (10, 11). 
Serum amyloid A (SAA) is a well recognised
acute inflammatory biomarker in various conditions
such as infection, inflammation, malignancy (12).
SAA, detected by proteomics as a potential biomarker
in lung cancer, may promote metastasis in lung
carcinoma cell line in vitro and has increasing blood
levels at the early stage of cancer (13, 14). The
objective of this prospective study was to evaluate
whether soluble PD-1/PD-L1 and SAA1 are potential




This prospective study, approved by The Insti -
tutional Ethics Committee, included 115 eligible lung
cancer patients with advanced metastatic disease, 101
of them being non-small cell lung cancer (NSCLC)
patients: 77 EGFR wild-type (EGFRwt) NSCLC patients
on standard chemotherapy, 15 EGFR activating
mutation positive (EGFRmut) adenocarcinoma patients
treated with tyrosine kinase inhibitors, and 9 patients
with mPD-L1 Tumor Cells Expression ≥50% by IHH
analysis, clone 22C3, DACO who were responders to
immunotherapy, pembrolizumab, based on the RECIST
1.1 (Response Evaluation Criteria in Solid Tumors).
The remaining 14 patients had small cell lung cancer,
SCLC. We also analysed biomarkers’ concentration in
30 healthy middle-aged subjects, as a control population.
Sample collection
Blood samples were collected into lithium-he -
parin vacutainer tubes (BD Diagnostics, Wokingham,
UK). Plasma was separated by centrifugation at
1000xg RCF for 15 minutes and stored at -80 °C,
until analysis.
For the PD-L1 (B7-H1/CD274) determination
in plasma, DuoSet ELISA system (R&D Systems
Europe, Ltd. Abingdon, UK) was used, as a sandwich
enzyme-linked immunosorbent assay (ELISA) specific
for the human B7-H1T. The lower limit was 2.0 ng/L,
and the upper limit was 1250 ng/L. According to the
manufacturer’s data, reference values for healthy
people in heparin-plasma samples are 33–110 ng/L.
For human serum amyloid A1 (SAA1) concen -
tration in plasma, Duo Set ELISA system (R&D Systems
Europe, Ltd. Abingdon, UK) was used, as a sandwich
enzyme-linked immunosorbent assay (ELISA) specific
for the human SAA1 protein. Lower and upper limits
for the SAA1 analysis were 3.13 ng/mL and 50
ng/mL, respectively.
Statistical analysis
Analyzed biomarkers’ distributions deviated
from normal, Gaussian distribution, and their average
values were presented as medians and 25th–75th
percentile values. Non-parametric methods – Mann-
Whitney U test for two groups’ and Kruskal-Wallis
ANOVA for three groups’ comparison were used.
Kaplan-Meier survival analysis was performed to test
biomarkers’ capability, i.e. its cut-off values (selected
as an upper third value calculated for this patients’
group) to predict overall patients’ survival. The log-
rank test was selected for that analysis. Analyses were
to any other lung cancer subgroup, as well as the highest
average SAA1 value compared to other subgroups.
Conclusions: It seems that sPD-1/PD-L1 might be a potential
biomarker, prognostic and/or predictive, particularly in patients
treated with immunotherapy. Serum amyloid A1 has
potential to act as a good predictor of patients’ survival, as
well as a biomarker of a more advanced disease, with
possibly good capability to predict the course of disease
measured at different time points.
Keywords: sPD-L1, serum amyloid A1, biomarker, PD-
L1 positive NSCLC
sa PD-L1+ NSCLC uo~en je zna~ajno vi{i nivo sPD-L1 u
pore|enju sa drugim podtipovima karcinoma plu}a, kao i
najvi{a prose~na vrednost SAA1.
Zaklju~ak: sPD-1/PD-L1 bi mogao da bude potencijalni
biomarker, prognosti~ki i/ili prediktivni, posebno kod paci -
jenata le~enih imunoterapijom. Serumski amiloid A1 je
dobar prediktor pre`ivljavanja, i tako|e biomarker uzna -
predovale bolesti, sa mogu}im dobrim potencijalom da
predvidi tok bolesti ako se meri u razli~itim vremenskim
ta~kama. 
Klju~ne re~i: sPD-L1, serumski amiloid A1, biomarker,
PD-L1 pozitivan NSCLC
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carried out using SPSS 18.0 (IBM, New York, USA).
Statistical tests were formulated as two-sided and a P
value less than 0.05 All tests were 2-sided, and a P
value < 0.05 was considered statistically significant.
Results
Basic clinical data on the group of 115 lung
cancer patients – subjects’ age, gender, smoking
status, ECOG PS score and pathohistological type are
presented in Table I.
Significantly higher level of sPD-L1 in PD-L1+
patients responding to immunotherapy compared to
any other lung cancer group was found. At the same
time, the PD-L1+ group had the highest average
SAA1 value compared to other three NSCLC groups
(i.e. EGFRwt adenocarcinoma, squamous cell carci -
noma and EGFRmut adenocarcinoma sub groups), as
well as to SCLC (Table II). 
Concentrations of sPD-L1 and SAA1 for every
patient by distinct lung cancer subgroup are shown in
scatter plot diagrams so that one may estimate their
values compared to the upper reference limit
calculated from the healthy control population. 
Calculated upper reference limits for the healthy
middle-aged population were also presented in the
graph so that one may compare them visually with
patients’ values. Reference limits calculated by a
nonparametric method as 2.5th and 97.5th percentile
values for the healthy population (N= 30) were as
follows: sPD-L1: 31.0–182.5 ng/L and SAA1: 0.32–
8.40 mg/L. The number of patients with PD-L1
above the upper reference limit defined for healthy
people (182.5 ng/mL), for different groups respe -
ctively, was: PD-L1+ (100%), adenocarcinoma
(EGFRmut, 47%), adenocarcinoma (EGFRwt, 43%),
squamous cell carcinoma (64%) and SCLC (31%).
SAA1 values higher than the upper reference limit of
the healthy population were noted in 78% of PD-L1+
patients, 60% of adenocarcinoma (EGFRmut), 48%
adenocarcinoma (EGFRwt), 74% squamous cell
carcinoma and 64% of SCLC patients. 
The possible influence of different additional
Table I General demographic and clinical data of lung cancer patients.
Table II Blood sPD-L1 and SAA1 concentration in lung cancer subgroups.
P – from Mann-Whitney U test; aa,aaaP< 0.01, 0.001 vs Adenocarcinoma (EGFRwt) group; b,bbbP<0.05, 0.001 vs Adenocarcinoma
(EGFR+mutation) group; cccP< 0.001 vs Squamous cell carcinoma group, ddP<0.05, 0.01 vs PD-L1+ group
Characteristic Subgroups





Age, years <60/>60 22(22)/79(78) 8(57)/6(43)
Gender Male/Female 72(71)/29(29) 9(65)/5(35)
Smoking status Never/Current/Ex-smoker 9(8.9)/61(60)/31(31,1) 1(7)/10(71)/3(21)






Squamous cell carcinoma 31(31)
PD-L1+ NSCLC 9(9)
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Figure 1 Scatter plot diagram of sPD-L1and SAA1 values in subgroups of lung cancer patients.
Dashed lines indicate upper reference limit for the sPD-L1 and SAA1 values from control group population.
Figure 2 PD-L1 and SAA1 concentrations in NSCLC and SCLC subgroups according to 
A. Age (<60 y. and >60 y.), a,b,c P<0,05 vs <60y NSCLC, >60y NSCLC, <60y SCLC, respectively, and 
B. Gender (M-male, F-female), a-P<0.05 vs male group in NSCLC group.
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factors, such as gender and age on sPD-L1 and SAA1
concentrations was investigated, for the two main
lung cancer groups: NSCLC and SCLC. We selected
the age of as a cut-off value for age sub-groups. The
highest sPD-L1 concentration was found in younger
SCLC patients, compared with younger, as well as
older NSCLC patients; we noticed as well significantly
lower sPD-L1 in older than in younger SCLC patients
(Figure 2A). SAA1 concentration was significantly
higher in male subgroup compared to female, but
only for NSCLC patients. Other values in gender
subgroups did not differ among basic pathohystology
classes (Figure 2B). 
Further analysis has not shown any consistent
correlation with neither the number of initially present
metastases nor with the specific metastases localisation. 
In the NSCLC group, patients with clinically
more favourable response to chemotherapy (i.e.
complete response) had significantly lower SAA1
concentration compared to less favourable responses,
whereas sPD-L1 did not differ according to the
therapy outcome. 
In the SCLC group no patients with complete
response to therapy were noted. However, sPD-L1
concentration was significantly higher (P<0.05) in
the stable disease group compared to partial
responders (which is a clinically better status). There
was no difference in SAA1 concentration among
different therapy response subgroups in this patho -
histological lung cancer type. 
In order to test biomarkers’ capability to predict
overall patients’ survival, we implemented Kaplan-
Meier survival analysis in NSCLC EGFRwt patients
Figure 3 Kaplan-Meier analysis of overall survival in NSCLC EGFRwt patients during 12 months of study for the sPD-L1, and
SAA1 values. 
Table III Blood sPD-L1and SAA concentrations in relation to response to chemotherapy in two lung cancer groups, NSCLC
























































P<0.05, 0.001, respectively compared to complete response in NSCLC group; * - P<0.05 vs partial response sub-group in SCLC;
Mann Whitney U test 
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throughout the 12 months of study for the sPD-L1,
and SAA1 according to its cut-off values selected as
upper tertile value for the whole patients’ group
(Figure 3).
SAA1 is a significant predictor of patients’
survival according to Kaplan-Meier analysis; our
current results showed that patients with SAA1 higher
than 15 mg/L had shorter survival compared to
patients with lower SAA1 values. Overall survival of
the lung cancer patients with high SAA1 values at the
study beginning was 7.4 months compared to 10.1
months in patients with lower SAA1 values. 
Discussion
Tumours effectively suppress immune responses
by activating negative regulatory pathways, check -
points that are essential for immune homeostasis, or
by adopting features that enable them to actively
escape detection (3, 15). The cell-surface Programmed
Death receptor 1 (membrane, mPD-1) is expressed
by T cells on activation in the presence of tumour
cells and binds to one of two ligands, PD-L1 and PD-
L2. A lot of types of cells can express membrane PD-
L1, including tumour cells and immune cells. Binding
of PD-L1 or PD-L2 to PD-1 represents an inhibitory
signal that prevents the activity of anti-tumour
effectors T cells, why the PD-L1/PD-1 axis became
very important for restricting tumour immunity. 
It has been revealed recently that membrane-
bound PD-1 and PD-L1 also have soluble forms,
(sPD-1/sPD-L1), detected in the blood of patients
with different kinds of tumours (16). 
It was supposed that sPD-L1 could be released
or shed from mPD-L1-positive tumour cells or
immune cells (17, 18). However, the accurate source
of a soluble form of PD-L1 is not confirmed. The
sPD-L1 is detectable in supernatants from mPD-L1
expression positive cell lines rather than in those from
mPD-L1 expression negative cell lines (20). This
finding indicates that mPD-L1 tumour cells might be
a source of sPD-L1, but at the same time, other
sources of sPD-L1 like immune cells cannot be
excluded (20–23). 
Many studies’ objective is to elucidate the
biological significance of sPD-1/PD-L1 in human
cancers and to evaluate whether they are potential
diagnostic, predictive, or prognostic biomarkers.
Increasing evidence suggests that blood levels of
sPD-1/PD-L1 might facilitate the prediction of
tumour behaviour characteristics, response to
treatment, and survival outcomes in cancer patients
(5, 16). 
Here, we have reported significantly higher
concentrations of sPD-L1 in the serum of lung cancer
patients compared with the healthy control group.
The average rate of values higher than the upper
reference limit in healthy people was in total 53.0%
(61/115), similar to findings in other published
results (4, 5, 18) (Figure 1).
An interesting finding was the relation between
the age and sPD-L1 concentration in lung cancer
patients. Our findings regarding age have shown
significantly higher sPD-L1 values in SCLC patients
younger than 60, compared to each of NSCLC
patients’ subgroups. So, NSCLC and SCLC patients
did not have the similar pattern of this parameter’s
change with ageing: NSCLC patients had no signifi -
cant changes of sPD-L1 values with ageing, while
contrary to published data for healthy population with
increasing sPD-L1 values with ageing (19), older
patients with SCLC had decreased sPD-L1 values
compared to their younger counterparts (Figure 2).
The exact role and precise functions of sPD-L1
in cancer have not been determined yet. It has been
proved that sPD-L1 still keeps its biological activity
and is able to specifically bind to PD-1 receptor in
peripheral blood, thus activating the PD-1/PD-L1
pathway with possibly consequent systemic immuno -
suppressive effect (16). 
The exact role of sPD-L1 findings is being
explored by an increasing number of studies, however
with somewhat conflicting results (24–29). 
Our study has shown a trend in the correlation
of higher sPD-L1 blood level with more advanced
disease stage (Table III), however without any
consistent correlation with neither the number of
initially present metastases nor with the specific meta -
stases localisation. Regarding survival prediction,
Kaplan-Meier analysis of overall survival of NSCLC
patients according to the cut-off value of sPD-L1,
failed to demonstrate significant survival predictive
capability of sPD-L1, although patients with higher
sPD-L1 values had shorter overall survival compared
with subjects with lower sPD-L1 concentration (8.3
months vs 9.1 months, respectively) (Figure 3). 
Some studies have reported that increased sPD-
L1 levels might implicate a poor prognosis or treat -
ment resistance (5, 24), and that cancer patients with
low sPD-L1 levels may have a longer survival time
(27, 28), contrary to the finding that patients with
higher levels of sPD-L1 had better prognosis than the
low-level patients did (26). 
Zhang et al. (27) reported significantly different
average blood levels of sPD-L1 in patients with
advanced NSCLC vs healthy controls (P<0.001),
while the median overall survival (OS) in the low –
versus high-level sPD-L1 group was significantly
higher (26.8 vs 18.7 months). The expression of PD-
L1 in the study correlated considerably with abdo -
minal organ metastasis. Prognostic significance of
circulating soluble PD L-1 in patients with malignan -
cies has been analysed recently in two meta-analyses
as well (17, 28). 
Eight studies and 1,102 cancer patients were
included in the final analysis of Ding et al. (28), and
the findings indicated that a higher level of sPD-L1
was associated with worse overall survival. Subgroup
analysis has shown significant differences in the cancer
type (hematological neoplasms or non-hematological
neoplasms), sample size (more or less than 100), a
cut-off value of sPD-L1 (more or less than 6.51 ng/mL)
and ethnicity (Asian or European). A total of 1040
patients with solid tumours from 8 eligible studies
were included in the other meta-analysis, and the
pooled HR suggested that a high blood level of
soluble sPD-L1 significantly correlated with worse
overall survival. 
As for lung cancer, it has been found that high
expression of sPD-L1 was associated with the pre -
sence of epidermal growth factor receptor (EGFR)
mutations in surgically resected NSCLC, this being an
independent negative prognostic factor (29).
Contrary to the above, our results, although based
on small series of EGFR mutation positive adeno -
carcinoma, had shown lower blood sPD-L1 levels in
EGFR mutation positive NSCLC than in EGFRwt
NSCLC, 134.4 ng/L vs 161.4 ng/L respectively. This
difference was not statistically significant.
Zhao et al. (29) evaluated the sPD-L1 levels at
diagnosis and during thoracic radiotherapy, in 126
inoperable, locally advanced NSCLC patients, and
observed that the lower baseline sPD-L1 level
significantly correlated with longer OS, shown to be
an independent prognostic biomarker for this group
of NSCLC patients. 
In our study, although sPD-L1 did not demon -
strate significant survival predictive capability, we have
obtained interesting results in 9 patients with mPD-L1
expression ≥50%. Although it was a too small
number of patients, it was a striking finding in all 9
patients responders to immunotherapy of far much
higher blood sPD-L1 concentrations compared to
either EGFRwtNSCLC or EGFR mutation positive
adenocarcinoma. It might be supposed that those
results point to possible immunotherapy efficacy with
consequent proteolytic cleavage of the membrane-
bound form PD-L1 into circulation. Unfortunately, we
did not have an opportunity to perform sPD-L1
determination before the onset of immunotherapy,
which we intend to explore in the future. We will tailor
the study in which IHH PD-L1+ tumour patients will
be assigned to sPD-L1 analysis before the beginning
of immunotherapy.
Regarding blood levels sPD-L1 determination, it
must be emphasised that different methods with
different cut-off values have been used in all these
studies. Very recently, it has been demonstrated that
circulating immunosuppressive tumour-derived
exosomes play a key role in immune suppression and
disease progression, and that elevated PD-L1 levels
and PD-L1 mRNA expression on exosomes correlate
with response to anti-PD-1/PD-L1 immunotherapy in
melanoma and NSCLC patients providing a rationale
for the application of exosomal PD-L1 as a predictor
for anti-PD-1 therapy (30, 31).
Not only were different methods with different
cut-off values used in all these studies but also
important diverse ethnic populations and different
patient populations as well may have influenced, at
least in part, the results and the interpretation of
findings.
Based on the observation that chronic inflam -
mation was associated with tumour progression, it
was postulated that many inflammatory parameters
could serve as prognostic biomarkers for some tumours
(8, 9), with lung cancer among those (7, 32).
Several studies have found that SAA could
distinguish lung cancer patients from healthy controls
and predict prognosis, thus being a potential
diagnostic and prognostic biomarker for lung cancer
(33, 34). 
In our study, the SAA1 concentration was
significantly higher in male subgroup compared to
female, but only for NSCLC patients (Figure 2).
Comparing SAA concentrations concerning patients’
response to chemotherapy, no significant difference
was found (Table III). 
However, a significantly higher level of sPD-L1
in PD-L1+ patients responding to immunotherapy
compared to any other lung cancer group was found.
At the same time, the PD-L1+ group also had the
highest average SAA1 values compared to the other
three groups (i.e. adenocarcinoma, squamous cell
carcinoma and EGFR+ groups) (Table III). It might
imply that elevated SAA1 levels evidently reflect
hyper-activation of the immune system in IHH mPD-
L1 tumour positive patients responding to immuno -
therapy. This clearly points to the immune-inflamed
phenotype of a tumour which generally correlates
with higher response rates to anti-PD-L1/PD-1
therapy (35–39). Although three basic immune
pheno types can be distinguished (immune-inflamed
tumours, immune-desert, and immune-excluded
tumours), there is a wide span of cytokines, chemo -
kines and tumour-associated cell types that influence
whether sufficient inflamma tion was present to foster
a desirable anti-tumour immune response following
immunotherapy. The level of inflamma tion can vary
widely changing over time (35).
Kaplan-Meier analysis of overall survival of
NSCLC patients according to cut-off values of two
selected biomarkers showed that SAA1 was a better
predictor of patients’ survival, showing good
capability to predict overall survival at the upper tertile
value as a cut-off value of 15 mg/L (log-rank 5.7,
P<0.05). Our results showed that patients with SAA1
values below 15 mg/L lived longer, 10 months vs 7
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months averagely in patients with SAA1 above 15
mg/L (Figure 3).
The level of SAA was found to be progressively
increased with the clinical stages of lung cancer (32).
Sung et al. (40) identified SAA1 and SAA2 in the
pooled sera of lung cancer patients and found about
14-fold higher levels of SAA in lung cancer patients’
blood samples compared to healthy controls. There is
evidence that macrophages could stimulate cancer cells
to produce IL-1  and IL-6, which in turn stimulate
lung cancer cells to induce SAA1/2.
Serum levels of MMP-2, CRP and SAA were
significantly higher in metastatic NSCLC patients than
in localised NSCLC patients (12). 
A systematic evaluation and meta-analysis
showed that an increased SAA serum level correlated
with lung cancer diagnosis (P<0.001), especially with
the squamous cell carcinoma (p = 0.012) (14).
Squamous cell lung cancer displayed a much higher
SAA level than adenocarcinoma and SCLC, pointing
to the potential of using SAA for discerning squamous
cell lung cancer from other types. This is contrary to
our findings of similar SAA values in a squamous cell
and SCLC, higher than in adenocarcinoma, but
significantly lower than in IHH mPD-L1 tumour
positive lung cancer (Table II).
There are several limitations to our study. The
sample size is rather small, so sampling error may
render a less reliable explanation of results and
conclusions. Also, we did not have the opportunity to
perform sPD-L1 and SAA1 determination before the
onset of treatment, particularly immunotherapy, as
well as IHH test of mPD-L1 expression for all EGFRwt
NSCLC tumours. Thus, the results have still to be
explored and validated in a much larger number of
lung cancer patients with different tumour types and
at different time points (at the time of diagnosis,
during and after different treatment modalities,
during follow up), with necessary comparison of
blood sPD-L1 levels not only with clinical
characteristics, but also within the same group of
patients with corresponding tumor biopsy mPD-L1
expression. 
Furthermore, patients included in this study are
Caucasians only, while the majority of discussed
studies are dealing with patients of Asian ethnicity,
which may influence the results with population bias.
Experience from oncogene driver mutations, more
studies with well-defined specific area patients should
be performed in order to obtain more generalizable
results. Largely varied cut-off values of sPD-L1
among published studie, which need clarification and
methodology validation are another serious and
obvious problem.
Conclusion 
Our study revealed significantly higher concen -
trations of sPD-L1 and SAA1 in the serum of lung
cancer patients compared with healthy control group.
Significantly higher level of sPD-L1 in PD-L1+
patients and responders to immunotherapy was
observed compared to any other lung cancer
subgroup, and the highest average SAA1 value
compared to other subgroups as well. It may be
speculated that sPD-1/PD-L1 might provide new
biomarkers, prognostic and/or predictive, particularly
in patients treated with immunotherapy only, or in
combination with other anticancer agents. This study
points clearly to its potential of SAA1 to act as good
predictor of patients’ survival, as well as a biomarker
of a more advanced disease, measured at different
time points.
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